Svartengren et al., 2000 - Google Patents
Medicinal particlesSvartengren et al., 2000
- Document ID
- 3067858671391275559
- Author
- Svartengren M
- Svartengren K
- Publication year
- Publication venue
- LUNG BIOLOGY IN HEALTH AND DISEASE
External Links
Snippet
The area of the adult lung that is exposed to the environment ranges from 40 to 120 m2. The conducting airways have a total area of less than 1 m2. An increased interest of use of the inhalation route has been seen over the years. For example, with beta-adrenergic agonists …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S514/00—Drug, bio-affecting and body treating compositions
- Y10S514/826—Asthma
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5049389A (en) | Novel liposome composition for the treatment of interstitial lung diseases | |
| KR100947409B1 (en) | Formoterol Superfine Formulation | |
| JP4990929B2 (en) | Inhalation and instillation of semifluorinated alkanes as carriers of active ingredients in the intrapulmonary region | |
| JP3480736B2 (en) | Use of mometasone furoate for the treatment of airway channels and lung disease | |
| JP2002532430A (en) | Treatment of severe chronic bronchitis (bronchiectasis) using aerosolized antibiotics | |
| AU2007297691B2 (en) | Pulmonary surfactant formulations and methods for promoting mucus clearance | |
| JP2001518518A (en) | Dry powder pharmaceutical composition of secretory leukocyte protease inhibitor | |
| KR20010042531A (en) | Pulmonary and Nasal Delivery of Raloxifene | |
| JP2008525490A (en) | Lung surfactant formulation | |
| US20060251711A1 (en) | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal | |
| Ruijgrok et al. | Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats | |
| CA3159515A1 (en) | Treatment of lower airways disorders | |
| US5863563A (en) | Treatment of pulmonary conditions associated with insufficient secretion of surfactant | |
| Waldrep et al. | Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition | |
| US20150071988A1 (en) | Sterically Stabilized Carrier For Aerosol Therapeutics, Compositions And Methods For Treating The Respiratory Tract Of A Mammal | |
| WALDREP et al. | Nebulized glucocorticoids in liposomes: aerosol characteristics and human dose estimates | |
| JP2021520396A (en) | Cyclosporine preparation for use in the treatment of obstructive bronchiolitis syndrome (BOS) | |
| Konduri et al. | The use of sterically stabilized liposomes to treat asthma | |
| US20230029342A1 (en) | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal | |
| JPWO2005004914A1 (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESPIRATORY DISEASE CONTAINING NF-κB DECOY AND METHOD OF USING THE SAME | |
| Svartengren et al. | Medicinal particles | |
| US20060204447A1 (en) | Small particle liposome aerosols for delivery of anticancer drugs | |
| US20010038825A1 (en) | Method and compositions for enhancing pulmonary function and treating pulmonary disorders | |
| EP1941883A1 (en) | Use of sodium blockers for an early therapy of obstructive lung diseases | |
| US9717752B2 (en) | Uses of antagonists of hyaluronan signaling |